Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Veracyte's Other Non Operating Income fell 18397.85% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 5931.42%. This contributed to the annual value of $9.6 million for FY2024, which is 456.28% up from last year.
  • Veracyte's Other Non Operating Income amounted to -$4.1 million in Q3 2025, which was down 18397.85% from $6.5 million recorded in Q2 2025.
  • Over the past 5 years, Veracyte's Other Non Operating Income peaked at $6.5 million during Q2 2025, and registered a low of -$4.1 million during Q3 2025.
  • Over the past 5 years, Veracyte's median Other Non Operating Income value was $1.2 million (recorded in 2021), while the average stood at $1.6 million.
  • Examining YoY changes over the last 5 years, Veracyte's Other Non Operating Income showed a top increase of 352857.14% in 2021 and a maximum decrease of 198571.43% in 2021.
  • Veracyte's Other Non Operating Income (Quarter) stood at $1.0 million in 2021, then surged by 94.78% to $2.0 million in 2022, then skyrocketed by 154.42% to $5.0 million in 2023, then plummeted by 114.54% to -$732000.0 in 2024, then plummeted by 454.23% to -$4.1 million in 2025.
  • Its Other Non Operating Income stands at -$4.1 million for Q3 2025, versus $6.5 million for Q2 2025 and $4.5 million for Q1 2025.